39 related articles for article (PubMed ID: 36852420)
1. Analysis of three characterization assays reveals ddPCR of LIN28A as the most sensitive for the detection of residual pluripotent stem cells in cellular therapy products.
Sun J; Yates C; Dingwall S; Ongtengco C; Power D; Gray P; Prowse A
Cytotherapy; 2024 May; ():. PubMed ID: 38934983
[TBL] [Abstract][Full Text] [Related]
2. ISSCR standards for the use of human stem cells in basic research.
Ludwig TE; Andrews PW; Barbaric I; Benvenisty N; Bhattacharyya A; Crook JM; Daheron LM; Draper JS; Healy LE; Huch M; Inamdar MS; Jensen KB; Kurtz A; Lancaster MA; Liberali P; Lutolf MP; Mummery CL; Pera MF; Sato Y; Shimasaki N; Smith AG; Song J; Spits C; Stacey G; Wells CA; Zhao T; Mosher JT
Stem Cell Reports; 2023 Sep; 18(9):1744-1752. PubMed ID: 37703820
[TBL] [Abstract][Full Text] [Related]
3. Induced pluripotent stem cells as a biopharmaceutical factory for extracellular vesicles.
Nishiga M; Guo H; Wu JC
Eur Heart J; 2018 May; 39(20):1848-1850. PubMed ID: 29547885
[No Abstract] [Full Text] [Related]
4. Multisite studies for validation and improvement of a highly efficient culture assay for detection of undifferentiated human pluripotent stem cells intermingled in cell therapy products.
Watanabe T; Yasuda S; Kusakawa S; Kuroda T; Futamura M; Ogawa M; Mochizuki H; Kikkawa E; Furukawa H; Nagaoka M; Sato Y
Cytotherapy; 2021 Feb; 23(2):176-183. PubMed ID: 32978066
[TBL] [Abstract][Full Text] [Related]
5. A novel in vitro method for detecting undifferentiated human pluripotent stem cells as impurities in cell therapy products using a highly efficient culture system.
Tano K; Yasuda S; Kuroda T; Saito H; Umezawa A; Sato Y
PLoS One; 2014; 9(10):e110496. PubMed ID: 25347300
[TBL] [Abstract][Full Text] [Related]
6. Highly sensitive droplet digital PCR method for detection of residual undifferentiated cells in cardiomyocytes derived from human pluripotent stem cells.
Kuroda T; Yasuda S; Matsuyama S; Tano K; Kusakawa S; Sawa Y; Kawamata S; Sato Y
Regen Ther; 2015 Dec; 2():17-23. PubMed ID: 31245455
[TBL] [Abstract][Full Text] [Related]
7. A selective cytotoxic adenovirus vector for concentration of pluripotent stem cells in human pluripotent stem cell-derived neural progenitor cells.
Hirai T; Kono K; Sawada R; Kuroda T; Yasuda S; Matsuyama S; Matsuyama A; Koizumi N; Utoguchi N; Mizuguchi H; Sato Y
Sci Rep; 2021 Jun; 11(1):11407. PubMed ID: 34075124
[TBL] [Abstract][Full Text] [Related]
8. International evaluation study of a highly efficient culture assay for detection of residual human pluripotent stem cells in cell therapies.
Watanabe T; Yasuda S; Chen CL; Delsing L; Fellows MD; Foldes G; Kusakawa S; Mouriès LP; Sato Y
Regen Med; 2023 Mar; 18(3):219-227. PubMed ID: 36852420
[No Abstract] [Full Text] [Related]
9. [In vitro tumorigenicity tests for process control of health care products derived from human induced pluripotent stem cells].
Sato Y
Yakugaku Zasshi; 2013; 133(12):1381-8. PubMed ID: 24292187
[TBL] [Abstract][Full Text] [Related]
10. The safety of human pluripotent stem cells in clinical treatment.
Simonson OE; Domogatskaya A; Volchkov P; Rodin S
Ann Med; 2015; 47(5):370-80. PubMed ID: 26140342
[TBL] [Abstract][Full Text] [Related]
11. Tumorigenicity studies for human pluripotent stem cell-derived products.
Kuroda T; Yasuda S; Sato Y
Biol Pharm Bull; 2013; 36(2):189-92. PubMed ID: 23370350
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
